The Mexican Soluble Ferric Pyrophosphate (SFP) patent grant covers the method and pharmaceutical composition for iron delivery administered in hemodialysis and peritoneal dialysis patients.
Based on previous FDA Phase II clinical study results and compared to intravenous (IV) iron administration, SFP delivered through dialysate, has shown to be a safe and effective method for maintaining optimal iron balance in dialysis patients while at the same time decreasing associated nursing and pharmaceutical IV iron administration costs.
Rockwell has licensed the exclusive world-wide rights to SFP and is collaborating with the FDA in its development. Rockwell has secured patents for SFP in multiple countries, including the US, Japan, and the EU, covering the largest commercial markets for iron supplementation in the world.